Reinforcing Global Commitment to Health Resilience, Ahead of the 26th DCVMN Annual General Meeting in Bali

Bandung, October 27, 2025 — As the 26th Annual General Meeting (AGM) of the Developing Countries Vaccine Manufacturers Network (DCVMN) approaches, to be held in Bali on October 29–31, 2025, the network reaffirms its commitment to advancing global health resilience.

The 26th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) in Bali will gather manufacturers, global health institutions, and partners under the theme ‘Advancing innovation and building a resilient vaccine ecosystem for a safer world’. DCVMN sees the AGM as a critical moment to amplify the voice of vaccine manufacturers from developing countries, to showcase their scientific and operational achievements, and to strengthen partnerships that translate innovation into locally relevant, sustainable vaccine supply.

All year long, DCVMN has worked to turn manufacturers’ real-world experiences into actionable solutions. DCVMN network has taken those on-the-ground perspectives into more than 150 formal meetings and committee sessions with international organizations and partners, and  CEO of DCVMN, Rajinder Suri, has represented DCVMN at several global conferences and forums worldwide to advocate for regulatory predictability, technology transfer, supply resilience, and equitable access.

DCVMN Working Groups, composed of subject-matter experts, produced three peer-reviewed publications this year for wider dissemination and generated practical outputs, including e-learning modules, technical analyses, and position papers, which have been shared with global stakeholders. Between 2015 and 2021, more than 115 South-to-South collaborations emerged, demonstrating the power of DCVM’s convening role to translate dialogue into joint action.

At the AGM, DCVMN will address a highly focused set of priorities that directly support the 26th AGM theme. Experts will examine how the global economic outlook for 2025 will impact public health financing and vaccine affordability. Sessions on regulatory strategies will explore ways to harmonise and make regulatory pathways more fit-for-purpose for manufacturers in low- and middle-income settings. Conversations about the future of immunization will look at new vaccines, technologies, and delivery models.

This AGM will spotlight Africa, with sessions on demand generation, unified procurement, and sustainable pricing to build resilience on the continent. Deliberations on the pandemic agreement and the Pandemic Fund will assess how global instruments can be operationalized to ensure manufacturers in developing countries are fully inclusive and supported. Innovation streams will showcase how AI, digital transformation, and novel technologies can accelerate vaccine development and manufacturing, and panels on financing will explore innovative mechanisms to close funding gaps. Across every session, the question will be practical: how does DCVMN turn innovation into innovating, developing, and manufacturing affordable vaccines and ensure timely delivery for populations in low-income and low-middle-income countries that need them most.

DCVMN’s aims for the AGM are threefold. First, to provide a unique, trusted platform where manufacturers from developing countries can be heard directly by the global fraternity and where those institutions can communicate opportunities and requirements transparently to the industry. Second, to catalyze new partnerships, both North-South and South-South collaborations that build and strengthen local and regional manufacturing capacity and create a more resilient ecosystem. Third, to create learning moments that expose manufacturers and partners to new science, technologies, and funding opportunities that could be adopted or adapted to local realities.

The DCVMN’s message to the global community is clear. Building a resilient vaccine ecosystem requires listening to and partnering with manufacturers in developing countries as they are the main suppliers to global vaccine players like Gavi, UNICEF, and PAHO, aligning regulatory and financing systems with what is feasible and necessary on the ground, and investing in technologies and partnerships that speed development and scale-up. When manufacturers are equipped, connected, and heard well in time, the global system stands to become more predictable, efficient, and fairer at delivering safe, effective & quality assured vaccines at affordable prices.

“Advancing innovation and building resilient vaccine ecosystems is not an abstract ambition. It is a practical imperative!” said Rajinder Suri, CEO of DCVMN. “In Bali, we are going to connect real-world experiences with the global tools, regulatory strategies, and strong partnerships & collaborations needed to ensure novel vaccines can be innovated, developed, manufactured, and delivered where they are needed most!”

As the co-host and one of the founding members of the Developing Countries Vaccine Manufacturers Network (DCVMN), Bio Farma reiterates its commitment to strengthening vaccine self-reliance and global health resilience, in line with DCVMN’s mission to improve public health.

Bio Farma’s President Director, Shadiq Akasya, emphasized that the AGM is a pivotal opportunity to strengthen strategic synergy among network members.

“As a co-host and part of DCVMN, Bio Farma is committed to making this forum a platform for strategic collaboration to strengthen a global vaccine ecosystem that is innovative, sustainable, and equitable. Through this meeting, we aim to demonstrate Indonesia’s tangible contribution to advancing global vaccine self-reliance,” he said.

He added that collaboration within DCVMN is not only about maintaining vaccine production independence but also ensuring fairer access for all countries worldwide.

“Through knowledge exchange, capacity building, and technological innovation, we have proven that vaccine manufacturers from developing countries can stand at the forefront of building equitable global health resilience,” he concluded.

Through the 26th DCVMN AGM in Bali on October 29–31, 2025, Bio Farma and DCVMN reaffirm their shared commitment to strengthening collaboration, driving innovation, and building a sustainable global health system to ensure equitable access to vaccines for all.

About DCVMN

The Developing Countries Vaccine Manufacturers Network (DCVMN) is a global alliance of 46 vaccine manufacturers from 17 developing countries, established in 2000 to strengthen public health through equitable access to high-quality vaccines.

DCVMN promotes collaboration among its members through advocacy, capacity building, professional training, and joint research initiatives, aimed at enhancing global immunization programs.

Working closely with international organizations such as WHO, UNICEF, GAVI, CEPI, PATH, CHAI, and the Gates Foundation, DCVMN strives to ensure that every nation has the capability to produce and supply affordable, life-saving vaccines. For further information, please visit dcvmn.org.

About Bio Farma

PT Bio Farma (Persero) is Indonesia’s state-owned life science company and the largest vaccine manufacturer in Southeast Asia.

Founded in 1890 and headquartered in Bandung, Bio Farma produces and supplies vaccines to more than 150 countries, while playing an active role in biotechnology research, innovation, and global health security.

As a member of DCVMN, Bio Farma continues to contribute to international collaboration to ensure equitable vaccine access and improved global public health. For further information, please visit www.biofarma.co.id.